We would like to share an important update about vorasidenib.
The Pharmaceutical Benefits Advisory Committee (PBAC) has decided not to recommend vorasidenib for PBS listing at this time.
We understand that this news may be both disappointing and concerning for you and your family, and we share in that disappointment.
Please be assured that we remain committed to addressing the feedback provided by the PBAC and working with the Department of Health, Disability and Aged care to make vorasidenib available on the PBS as soon as possible.
Servier is pleased that the PBAC has recognised the high unmet clinical need for effective treatments for IDH-mutant glioma. We also thank the IDH-mutant glioma community for their valuable input and sharing of lived experience, to help inform the PBAC, through the consumer comments process.
You can review the PBAC outcomes here
We deeply value the trust and support of patients and their families, and we remain dedicated to working towards equitable access to vorasidenib.
We will continue to keep you updated.
If you would like to get in touch, please contact sarah.collings@servier.com
